Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 7, 2013, Pages 1229-1240

  Natoli, Clara ^a   Vici, Patrizia ^b   Sperduti, Isabella ^b   Grassadonia, Antonino ^a   Bisagni, Giancarlo ^c   Tinari, Nicola ^a   Michelotti, Andrea ^d   Zampa, Germano ^e   Gori, Stefania ^f   Moscetti, Luca ^g   De Tursi, Michele ^a   Panebianco, Michele ^c   Mauri, Maria ^h   Ferrarini, Ilaria ^d   Pizzuti, Laura ^b   Ficorella, Corrado ⁱ   Samaritani, Riccardo ^e   Mentuccia, Lucia ^j   Iacobelli, Stefano ^a   Gamucci, Teresa ^j  

^a UNIVERSITY OF CHIETI   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Santa Maria Nuova Istituto di Ricovero e Cura A Carattere Scientifico Hospital   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^f SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^g BELCOLLE HOSPITAL   (Italy)

^h SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

ⁱ UNIVERSITY OF L'AQUILA   (Italy)

^j Medical Oncology Unit   (Italy)

more..

Author keywords

Breast cancer; HER2; Neoadjuvant; Pathological complete response; Survival; Trastuzumab

Indexed keywords

ANASTROZOLE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; LETROZOLE; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DISEASE FREE SURVIVAL; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ONCOGENE; HUMAN TISSUE; ITALY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MINIMAL RESIDUAL DISEASE; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84879217353     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1436-y     Document Type: Article

References (78)

1. Angelucci D, Tinari N, Grassadonia A, Cianchetti E, Ausili-Cefaro G, Iezzi L, Zilli M, Grossi S, Ursini LA, Scognamiglio MT, Castrilli G, De Tursi M, Noccioli P, Cioffi P, Iacobelli S, Natoli C (2012) Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. J Cancer Res Clin Oncol. doi: 10.1007/s00432-012-1325-9
2. Anton A, Ruiz A, Plazaola A, Calvo L, Segui MA, Santaballa A, Munoz M, Sanchez P, Miguel A, Carrasco E, Lao J, Camps J, Alfaro J, Antolin S, Camara MC (2011) Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol 22(1):74-79. doi: 10.1093/annonc/mdq317
3. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F (2012) Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9):2385-2393. doi: 10.1002/cncr.26555
4. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24(13):2019-2027. doi: 10.1200/jco.2005.04.1665 (Pubitemid 46622110)
5. Braunholtz DA, Edwards SJ, Lilford RJ (2001) Are randomized clinical trials good for us (in the short term)? Evidence for a trial effect. J Clin Epidemiol 54(3):217-224 (Pubitemid 32162034)
6. Brufsky A (2010) Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol 33(2):186-195. doi: 10.1097/COC.0b013e318191bfb0
7. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21(1):46-53
8. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-3685. doi: 10.1200/jco.2005.07.032
9. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-233. doi: 10.1158/1078-0432.ccr-06-1345 (Pubitemid 46121873)
10. Cance WG, Carey LA, Calvo BF, Sartor C, Sawyer L, Moore DT, Rosenman J, Ollila DW, Graham M 2nd (2002) Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 236(3):295-302. doi: 10.1097/01.sla.0000027526.67560.64
11. Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML (2005) American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97(15):1137-1142. doi: 10.1093/jnci/dji206 (Pubitemid 41511213)
12. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16(3):223-228 (Pubitemid 23184384)
13. Chumsri S, Jeter S, Jacobs LK, Nassar H, Armstrong DK, Emens LA, Fetting JH, Lange JR, Riley C, Tsangaris TN, Wolff AC, Zellars R, Zhang Z, Stearns V (2010) Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer 10(1):40-45. doi: 10.3816/CBC.2010.n.005
14. Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, Pruneri G, Veronesi P, Torrisi R, Cardillo A, Montagna E, Campagnoli E, Luini A, Intra M, Galimberti V, Scarano E, Peruzzotti G, Goldhirsch A (2009) Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 116(2):359-369. doi: 10.1007/s10549-008-0223-y
15. Costa RB, Kurra G, Greenberg L, Geyer CE (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 21(11):2153-2160. doi: 10.1093/annonc/mdq096
16. Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, Priou F, Gligorov J, Martin X, Trillet-Lenoir V, Weber B, Bleuse JP, Vasseur B, Serin D, Namer M (2007) Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 25(19):2678-2684. doi: 10.1200/jco.2006.09.9994 (Pubitemid 47123173)
17. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU (2007) Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 110(6):1195-1200. doi: 10.1002/cncr.22895 (Pubitemid 47435588)
18. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656-1664. doi: 10.1093/jnci/djr393
19. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
20. Engstrom C, Jamieson GG, Devitt PG, Irvine T, Watson DI (2012) Impact of participation in randomized trials on outcome following surgery for gastro-oesophageal reflux. Br J Surg 99(3):381-386. doi: 10.1002/bjs.8666
21. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7):2483-2493 (Pubitemid 27289876)
22. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672-2685 (Pubitemid 28363030)
23. Garnock-Jones KP, Keating GM, Scott LJ (2010) Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 70(2):215-239. doi: 10.2165/11203700-000000000-00000
24. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712):377-384. doi: 10.1016/s0140-6736(09)61964-4
25. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12(3):236-244. doi: 10.1016/s1470-2045(11)70033-x
26. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736-1747. doi: 10.1093/annonc/mdr304
27. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983-5992. doi: 10.1200/jco.2005.06.232
28. Hahn OM, Schilsky RL (2012) Randomized controlled trials and comparative effectiveness research. J Clin Oncol. doi: 10.1200/jco.2012.42.2352
29. Hannouf MB, Brackstone M, Xie B, Zaric GS (2012) Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor-positive, one-to-three positive axillary lymph node, breast cancer. Curr Oncol 19(5):e319-e328. doi: 10.3747/co.19.1038
30. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13(4):1198-1207. doi: 10.1158/1078-0432.ccr-06-1304 (Pubitemid 46424061)
31. Horiguchi J, Oyama T, Koibuchi Y, Yokoe T, Takata D, Ikeda F, Nagaoka H, Rokutanda N, Nagaoka R, Ishikawa Y, Odawara H, Kikuchi M, Sato A, Iino Y, Takeyoshi I (2009) Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer. Anticancer Res 29(2):517-524
32. Horiguchi J, Oyama T, Takata D, Rokutanda N, Nagaoka R, Odawara H, Tokiniwa H, Tozuka K, Kikuchi M, Sato A, Takeyoshi I (2011) Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. Anticancer Res 31(9):3041-3046
33. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. doi: 10.1016/j.ejca.2012.05.023
34. Hudis CA (2007) Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357(1):39-51. doi: 10.1056/NEJMra043186 (Pubitemid 47026733)
35. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Hogel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133-140. doi: 10.1007/s10549-010-1103-9
36. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24(12):1831-1838. doi: 10.1200/jco.2005.02.8886 (Pubitemid 46638980)
37. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13(9):869-878. doi: 10.1016/s1470-2045(12)70329-7
38. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
39. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24(12):1940-1949. doi: 10.1200/jco.2005.02.6187 (Pubitemid 46638994)
40. Kaufmann M, Morrow M, von Minckwitz G, Harris JR (2010) Locoregional treatment of primary breast cancer: consensus recommendations from an international expert panel. Cancer 116(5):1184-1191. doi: 10.1002/cncr.24874
41. Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW (2010) Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology 79(5-6):324-330. doi: 10.1159/000322192
42. Korn EL, Freidlin B (2012) Methodology for comparative effectiveness research: potential and limitations. J Clin Oncol. doi: 10.1200/jco.2012.44.8233
43. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460-469 (Pubitemid 29075229)
44. Lyman GH, Levine M (2012) Comparative effectiveness research in oncology: an overview. J Clin Oncol. doi: 10.1200/jco.2012.45.9792
45. Mariani G, Fasolo A, De Benedictis E, Gianni L (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6(2):93-104. doi: 10.1038/ncponc1298
46. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R (2006) Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66(16):8266-8273. doi: 10.1158/0008-5472.can-05-4045 (Pubitemid 44299196)
47. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97(3):188-194. doi: 10.1093/jnci/dji021 (Pubitemid 40277368)
48. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L (2007) Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25(19):2650-2655. doi: 10.1200/jco.2006.08.2271 (Pubitemid 47123169)
49. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12(5):320-327 (Pubitemid 37322062)
50. Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Leheurteur M, Gimbergues P, Tortochaux J, Cure H, Chollet P (2007) Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer. Oncologist 12(4):390-396. doi: 10.1634/theoncologist.12-4-390 (Pubitemid 46698716)
51. Peppercorn JM, Weeks JC, Cook EF, Joffe S (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363(9405):263-270. doi: 10.1016/s0140-6736(03)15383-4 (Pubitemid 38142408)
52. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S (2011) Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs 22(2):128-135
53. Pierga JY, Delaloge S, Espie M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretiere JM, Spielmann M, Savignoni A, Marty M (2010) A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 122(2):429-437. doi: 10.1007/s10549-010-0939-3
54. Precht LM, Lowe KA, Atwood M, Beatty JD (2010) Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 16(4):362-368. doi: 10.1111/j.1524-4741.2010. 00935.x
55. Robidoux A, Buzdar AU, Quinaux E, Jacobs S, Rastogi P, Fourchotte V, Younan RJ, Pajon ER, Shalaby IA, Desai AM, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Wolmark N (2010) A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 10(1):81-86. doi: 10.3816/CBC.2010.n.011
56. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4):320-368. doi: 10.1634/theoncologist.2008-0230
57. Ruiz M, Salvador J, Bayo J, Lomas M, Moreno A, Valero M, Bernabe R, Vicente D, Jimenez J, Lopez-Ladron A (2008) Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 62(6):1085-1090. doi: 10.1007/s00280-008-0709-7
58. Sanchez-Munoz A, Duenas-Garcia R, Jaen-Morago A, Carrasco E, Chacon I, Garcia-Tapiador AM, Ortega-Granados AL, Martinez-Ortega E, Ribelles N, Fernandez-Navarro M, de la Torre-Cabrera C, Duenas B, Rueda AI, Martinez J, Tortosa CR, Martin-Salvago MD, Sanchez-Rovira P (2010) Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination? Results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine±trastuzumab in stage II and III breast cancer patients. Am J Clin Oncol 33(5):432-437. doi: 10.1097/COC.0b013e3181b4eff9
59. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180(3):297-306
60. Schott AF, Hayes DF (2012) Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol 30(15):1747-1749. doi: 10.1200/jco.2011.41.3161
61. Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L (2011) Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol 37(10):856-863. doi: 10.1016/j.ejso.2011.07.003
62. Shimizu C, Masuda N, Yoshimura K, Tsuda H, Mano M, Ando M, Tamura K, Fujiwara Y (2009) Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer. Jpn J Clin Oncol 39(8):484-490. doi: 10.1093/jjco/hyp052
63. Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA (2009) Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 27(28):4693-4700. doi: 10.1200/jco.2008.21.4163
64. Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT (2010) The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 17(9):2411-2418. doi: 10.1245/s10434-010-1008-1
65. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414-4422. doi: 10.1200/jco.2007.10.6823 (Pubitemid 350013847)
66. Tanai C, Nakajima TE, Nagashima K, Kato K, Hamaguchi T, Yamada Y, Muro K, Shirao K, Kunitoh H, Matsumura Y, Yamamoto S, Shimada Y (2011) Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial. J Oncol Pract 7(3):148-153. doi: 10.1200/jop.2010.000106
67. Tarone RE (1975) Tests for trend in life table analysis. Biometrika 62:679-682
68. Tran B, Bedard PL (2011) Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 13(6):221. doi: 10.1186/bcr2904
69. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28(12):2024-2031. doi: 10.1200/jco.2009.23.8451
70. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, Muller V, du Bois A, Kuhn T, Stickeler E, Harbeck N, Hoss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29(25):3351-3357. doi: 10.1200/jco.2010.31.4930
71. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kuhn T, Nekljudova V, von Minckwitz G (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13(2):135-144. doi: 10.1016/s1470-2045(11)70397-7
72. Valachis A, Mauri D, Polyzos NP, Chlouverakis G, Mavroudis D, Georgoulias V (2011) Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 20(6):485-490. doi: 10.1016/j.breast.2011.06.009
73. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19(22):4224-4237 (Pubitemid 33081640)
74. von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M (2010) Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 28(12):2015-2023. doi: 10.1200/jco.2009.23.8303
75. von Minckwitz G, Untch M, Nuesch E, Loibl S, Kaufmann M, Kummel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Muller V, Juni P (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125(1):145-156. doi: 10.1007/s10549-010-1228-x
76. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796-1804. doi: 10.1200/jco.2011.38.8595
77. Wang Y, Li JJ, Di GH, Lu JS, Wu J, Liu GY, Hu XC, Wang ZH, Yang WT, Shao ZM (2010) Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer. Zhonghua Zhong Liu Za Zhi 32(11):864-867
78. Wildiers H, Neven P, Christiaens MR, Squifflet P, Amant F, Weltens C, Smeets A, van Limbergen E, Debrock G, Renard V, Van Eenoo L, Wynendaele W, Paridaens R (2011) Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol 22(3):588-594. doi: 10.1093/annonc/mdq406